CORDANI, NICOLETTA
CORDANI, NICOLETTA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
CENTRAL AND PERIPHERAL MICROVASCULAR NETWORK IS ABNORMAL IN RATS WITH PAINFUL-CHEMOTHERAPY INDUCED NEUROPATHY: NEW PATHOPHYSIOLOGICAL MECHANISMS OVER THE HORIZON?
2024 Carozzi, V; Rodriguez-Menendez, V; Pozzi, E; Canta, A; Chiorazzi, A; Cordani, N; Alberti, P; Meregalli, C; Longo, E; Saccomano, G; Tromba, G; Donà, E; Cavaletti, G; Zippo, A
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer
2024 Ilari, A; Cogliati, V; Sherif, N; Grassilli, E; Ramazzotti, D; Cordani, N; Cazzaniga, G; Di Bella, C; Lavitrano, M; Cazzaniga, M; Cerrito, M
Edaravone: A Novel Possible Drug for Cancer Treatment?
2024 Duranti, E; Cordani, N; Villa, C
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
2024 Villa, M; Malighetti, F; Sala, E; Sharma, G; Arosio, G; Gemelli, M; Manfroni, C; Fontana, D; Cordani, N; Meneveri, R; Zambon, A; Piazza, R; Pagni, F; Cortinovis, D; Mologni, L
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective
2023 Cordani, N; Bianchi, T; Ammoni, L; Cortinovis, D; Cazzaniga, M; Lissoni, A; Landoni, F; Canova, S
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study
2023 Meazza Prina, M; Gotuzzo, I; Cazzaniga, M; De Bernardi, E; Cafaro, P; Capici, S; Cogliati, V; Fulvia Pepe, F; Cicchiello, F; Riva, F; Cordani, N; Cerrito, M; Turolla, E; Landoni, C; Elisei, F; Crivellaro, C; Virdone, L; Monaco, L; Guidi, A; Guerra, L
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC)
2023 Cordani, N; Lisini, D; Coccè, V; Paglia, G; Meanti, R; Cerrito, M; Tettamanti, P; Bonaffini, L; Paino, F; Alessandri, G; Marcianti, A; Giannì, A; Villa, C; Mauri, M; Mologni, L; Torsello, A; Pessina, A; Cazzaniga, M
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells
2023 Cordani, N; Mologni, L; Piazza, R; Cogliati, V; Pepe, F; Capici, S; DI BELLA, C; Jaconi, M; Cerrito, M; Villa, M; Tettamanti, P; Cavaletti, G; Lavitrano, M; Cazzaniga, M
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells
2023 Cordani, N; Mologni, L; Piazza, R; Tettamanti, P; Cogliati, V; Mauri, M; Villa, M; Malighetti, F; DI BELLA, C; Jaconi, M; Cerrito, M; Cavaletti, G; Lavitrano, M; Cazzaniga, M
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation
2022 Scagliotti, A; Capizzi, L; Cazzaniga, M; Ilari, A; De Giorgi, M; Cordani, N; Gallazzi, M; Bruno, A; Pelosi, G; Albini, A; Lavitrano, M; Grassilli, E; Cerrito, M
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons
2022 Cortinovis, D; Colonese, F; Abbate, M; Sala, L; Meazza Prina, M; Cordani, N; Sala, E; Canova, S
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
2022 Cogliati, V; Capici, S; Pepe, F; Di Mauro, P; Riva, F; Cicchiello, F; Maggioni, C; Cordani, N; Cerrito, M; Cazzaniga, M
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
2022 Pepe, F; Cazzaniga, M; Baroni, S; Riva, F; Cicchiello, F; Capici, S; Cogliati, V; Maggioni, C; Cordani, N; Cerrito, M; Malandrin, S
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
2022 Cazzaniga, M; Capici, S; Cordani, N; Cogliati, V; Fulvia Pepe, F; Riva, F; Cerrito, M
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy
2022 Villa, M; Malighetti, F; Sharma, G; Arosio, G; Sala, E; Manfroni, C; Fontana, D; Cordani, N; Meneveri, R; Zambon, A; Piazza, R; Pagni, F; Cortinovis, D; Mologni, L
Metronomic chemotherapy
2021 Cazzaniga, M; Cordani, N; Capici, S; Cogliati, V; Riva, F; Cerrito, M
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib
2019 Sharma, G; Cortinovis, D; Agustoni, F; Arosio, G; Villa, M; Cordani, N; Bidoli, P; Bisson, W; Pagni, F; Piazza, R; Gambacorti-Passerini, C; Mologni, L
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer
2018 Redaelli, S; Ceccon, M; Zappa, M; Geeta, G; Mastini, C; Mauri, M; Nigoghossian, M; Massimino, L; Cordani, N; Farina, F; Piazza, R; Gambacorti-Passerini, C; Mologni, L
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
2017 Piazza, R; Ramazzotti, D; Spinelli, R; Pirola, A; De Sano, L; Ferrari, P; Magistroni, V; Cordani, N; Sharma, N; Gambacorti-Passerini, C
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes
2017 Piazza, R; Ramazzotti, D; Spinelli, R; Pirola, A; De Sano, L; Ferrari, P; Magistroni, V; Cordani, N; Sharma, N; GAMBACORTI PASSERINI, C